Colorectal disorders:
Indications for: ZORBTIVE
Short bowel syndrome in conjunction with nutritional support (see full labeling).
Adult Dosage:
Rotate inj site. Initially 0.1mg/kg SC inj once daily; max 8mg/day. Treat for 4 weeks. If fluid retention or arthralgia occurs; reduce dose by 50%. Discontinue therapy for up to 5 days if severe toxicities occur; if resolved, resume at 50% of original dose; if unresolved within 5 days or recurs, discontinue permanently.
Children Dosage:
Not established.
ZORBTIVE Contraindications:
Active malignancy. Acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure. Active proliferative or severe non-proliferative diabetic retinopathy.
ZORBTIVE Warnings/Precautions:
Monitor for potential malignant changes of preexisting nevi. Increased mortality in those with acute critical illness (see Contraindications). Impaired glucose tolerance/diabetes mellitus: monitor blood glucose. Hypoadrenalism: monitor serum cortisol levels. Evaluate thyroid function in those with hypopituitarism before starting and after 4 weeks treatment; correct thyroid function, if needed. Perform funduscopic evaluation for intracranial hypertension at initiation; discontinue if papilledema occurs. Elderly. Pregnancy. Nursing mothers.
ZORBTIVE Classification:
Growth hormone (GH).
ZORBTIVE Interactions:
May antagonize glucocorticoids. Concomitant antidiabetic treatment may need to be adjusted.
Adverse Reactions:
Edema (eg, facial, peripheral), arthralgia, inj site pain, flatulence, abdominal pain, vomiting, pain, nausea; hypersensitivity reactions, tissue turgor (swelling in hands/feet), musculoskeletal discomfort, carpal tunnel syndrome (reduce dose or discontinue if unresolved), acute pancreatitis.
How Supplied:
Vials—1 (w. diluent)
